Polybrominated diphenyl ethers (PBDEs) in U.S. mothers' milk. by Schecter, Arnold et al.
Synthetic halogenated compounds, including
some of the persistent organic pollutants
(POPs) such as chlorinated dioxins, dibenzo-
furans, and polychlorinated biphenyls (PCBs),
have been identiﬁed as global environmental
and human contaminants over the past 30
years. Some brominated ﬂame retardants can
also be persistent synthetic environmental
contaminants. Within this group, brominated
diphenyl ethers (BDEs) are one class of
brominated flame retardants used in large
amounts in the United States. Three commer-
cial products are available: penta-BDE, octa-
BDE, and deca-BDE. They are used as ﬂame
retardants in electrical appliances, including
television sets, computers, computer printers,
and fax machines, as well as in carpets and fur-
niture upholstery [Bromine Science and
Environmental Forum (BSEF) 2001]. These
commercial mixtures differ in content of spe-
ciﬁc polybrominated diphenyl ether (PBDE)
congeners, which in turn differ in their
bioavailability, bioaccumulation, and toxico-
logic properties (de Wit 2002; Hardy 2002a,
2002b; McDonald 2002).
Regarding available commercial prod-
ucts, deca-BDE consists almost exclusively of
deca-substituted BDE-209 (97%), with some
3% nona-BDE. In 2001, about 24,500 metric
tons of penta-BDE was marketed in the United
States. Smaller amounts of octa-BDE and
penta-BDE mixtures are produced, 1,500 and
7,100 tons a year, respectively (BSEF 2001).
Octa-BDE commercial mixtures include some
hexa-BDE but mainly hepta-BDE and
octa-BDE congeners, some nona-BDE and a
very small amount of deca-BDE congeners.
Almost all (98%) of the global penta-BDE is
produced and used in the United States (BSEF
2001). The major use for penta-BDE has been
in ﬂame-retarding polyurethane foam, which is
widely used in furniture upholstery. It consists
of tetra-, penta-, and hexa-brominated con-
geners, especially BDE-47 (tetra), BDE-99
(penta), and BDE-153 (hexa), but also
BDE-100 (penta) and BDE-154 (hexa) (Hale
et al. 2002; de Wit 2002).
Lower brominated congeners, the tetra-
BDEs and penta-BDEs, bioaccumulate to a
greater degree than do the higher brominated
BDEs such as deca-BDE. This may be caused
by degradation of higher brominated congeners
[International Program on Chemical Safety
(IPCS) 1994]. Although the debromination of
deca-BDE occurs under experimental condi-
tions, it is not clear whether this decomposi-
tion occurs in the environment (Eriksson et
al. 1998; Olsman et al. 2002). Results of a
2-year chronic rodent bioassay suggest that
the deca-BDE mixture may be a possible
human carcinogen, although this effect was
observed in laboratory animals only at very
high levels of exposure [National Toxicology
Program (NTP) 1986]. Octa-BDE and
penta-BDE are more bioactive, with possible
endocrine, hepatic, reproductive, and neuro-
developmental toxicities (Branchi et al. 2002;
Darnerud and Thuvander 1999; Darnerud et
al. 2001; Eriksson et al. 1998, 1999, 2001;
Fowles et al. 1994; Gillner and Jakobsson
1996; Hallgren and Darnerud 1998, 2002;
Hallgren et al. 2001; Hardy 2002a, 2002b;
Howie et al. 1990; McDonald 2002; Meerts
et al. 1998, 2001, 2002; Morse et al. 1993;
Pijnenburg et al. 1995).
Although levels of the dioxins, dibenzo-
furans, PCBs, and other organochlorines
appear to be decreasing in humans living in
industrialized countries over the past decades
(Fürst 2001; Fürst and Päpke 2002; Fürst et
al. 1994; Liem et al. 1995; Päpke 1998;
Schecter et al. 2000; Smith 1999), levels of
BDEs seem to be rising in some European
countries (Noren and Meironyte 1998, 2000).
Recently, the lower brominated PBDEs have
been found in humans, in a small number of
U.S. studies of blood and adipose tissue
(Mazdai et al. 2003; Petreas et al. 2003; She et
al. 2000, 2002;  Sjödin et al. 2001) and
Canadian milk studies (Ryan and Patry 2000,
2001; Ryan et al. 2002). Six congeners
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No previous reports exist on polybrominated diphenyl ether (PBDE) congeners in human milk
from individual U.S. mothers. This article on PBDEs is an extension of our previous studies on
concentrations of dioxins, dibenzofurans, polychlorinated biphenyls, and other chlorinated
organic compounds in human milk in a number of countries. PBDE commercial products are
used as flame retardants in flexible polyurethane foam (penta-BDE), in acrylonitrile-butadiene-
styrene resins (octa-BDE), and in high-impact polystyrene resins (deca-BDE). Their use is permit-
ted in the United States but is banned in some European countries because of presumed toxicity,
demonstrated persistence, and bioaccumulation. Different commercial products can be found in
various consumer products such as television sets, computers, computer monitors and printers,
carpets, and upholstery. Analyses of human levels of these compounds suggest low but rising levels
in European human milk, which may have peaked, at least in Sweden, in the late 1990s. Very few
data exist on levels of PBDEs in humans in the United States, and none from milk from individ-
ual nursing mothers. To address this issue, we analyzed 47 individual milk samples from nursing
mothers, 20–41 years of age, from a milk bank in Austin, Texas, and a community women’s
health clinic in Dallas, Texas. Up to 13 PBDE congeners were measured. The concentrations of
the sum of PBDE congeners varied from 6.2 to 419 ng/g (or parts per billion) lipid, with a median
of 34 ng/g and a mean of 73.9 ng/g lipid. The PBDE levels in breast milk from Texas were similar
to levels found in U.S. blood and adipose tissue lipid from California and Indiana and are 10–100
times greater than human tissue levels in Europe. Their detection in breast milk raises concern for
potential toxicity to nursing infants, given the persistence and bioaccumulative nature of some of
the PBDE congeners. These results indicate a need for more detailed investigation of the levels of
PBDE in people and food, as well as determining if animal fat in food is the major route of expo-
sure of the general U.S. population. Other routes of intake may also be significant. Key words:
brominated diphenyl ethers, brominated ﬂame retardants, human milk, nursing mothers. Environ
Health Perspect 111:1723–1729 (2003). doi:10.1289/ehp.6466 available via http://dx.doi.org/
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Research | Article(BDE-47, BDE-99, BDE-100, BDE-153,
BDE-154, and BDE-183) were measured in
12 fetal–maternal pairs in Indiana (Mazdai et
al. 2003). Five congeners (BDE-47, BDE-99,
BDE-100, BDE-153, and BDE-154) were
measured in 23 adipose tissue samples col-
lected from women living in the San Francisco
Bay (California) area (She et al. 2000, 2002).
She et al. (2002) measured the most prevalent
congener, BDE-47, in 32 adipose and 50
serum samples. BDE-47 levels in these
California women ranged from 5 to 510 ng/g
(or parts per billion) lipid, with a median of
16.5 ng/g (Petreas et al. 2003). Levels of
PBDEs (sum of seven congeners) in Canadian
milk increased by about an order of magni-
tude between 1992 and 2002, from 3.0 ng/g
(n = 72) to 22 ng/g (n = 92) (Ryan et al.
2002). Although human fat, blood, and milk
levels detected in European countries are
about 10 times lower than those found in
Canada or the United States, in Sweden, for
example, PBDE levels showed an exponential
increase over the period from 1972 to 1997—
from 0.07 ng/g to 4.02 ng/g in human milk
(sum of nine BDE congeners), doubling about
every 5 years (Meironyté Guvenius et al.
1999). A 9-fold increase in PBDE levels from
1977 to 1999 was observed in Norwegian
stored blood samples (Thomsen et al. 2002).
PBDE levels peaked in Sweden in 1997, after
which a slight decrease was observed. This
may have been the result of a “voluntary” ban
on penta-BDE products in Sweden (Betts
2002) and some other European countries
since the early 1990s. Levels in blood and milk
in other European countries are similar to
Swedish levels (Darnerud et al. 1998, 2002;
Jakobsson et al. 2002; Schroeter-Kermani et
al. 2000; Strandman et al. 2000; van Bavel et
al. 2002). Comparison of the measured levels
in most of these studies may be limited by the
relatively small number of samples, different
sampling procedures, and analysis conducted
in laboratories using different methodologies.
However, it is highly unlikely that the magni-
tude of the observed difference is only because
of methodologic differences. The European
Union (EU) will officially ban production,
use, and import of penta-BDE and octa-BDE
products in 2004 (European Parliament
2002). The decision about the ban of deca-
BDE, which is still extensively used, is pend-
ing the outcome of the EU risk assessment.
BDE-47, BDE-99, BDE-100, and some-
times BDE-153 or BDE-154 dominate in
environmental and human samples. BDE-47,
BDE-99, BDE-153, and BDE-154 are major
components of penta-BDE products. BDE-
153 and BDE-154 are also found in octa-
BDE. It is not clear how these relatively
persistent toxic chemicals enter humans. With
dioxins and dioxin-like chemicals, almost all
enter the general population through the food
chain, through meat, ﬁsh, or dairy products, as
do many other fat-soluble chemicals. PBDEs
may enter humans through food (Darnerud et
al. 2001), by ingestion of dust (Knoth et al.
2002; Leonards et al. 2001), or by inhalation
of some BDE congeners at home or on a job in
the electronics and computer industries
(Jakobsson et al. 2002; Johnson and Olson
2001; Sjödin et al. 1999, 2001, 2003). Dermal
absorption in nonoccupational settings seems
unlikely to substantially contribute to the ele-
vated PBDE levels in the general population.
Although considerable data exist docu-
menting the toxicity of dioxins, dibenzofu-
rans, and PCBs [Agency for Toxic Substances
and Disease Registry (ATSDR) 1994, 1998,
2000; International Agency for Research on
Cancer (IARC) 1997; Institute of Medicine
1996, 1998, 2002; Schecter 1994; Schecter
and Gasiewicz 2003; U.S. Environmental
Protection Agency (EPA) 1984], fewer data
exist on the toxicology of PBDEs. However,
the information available does indicate the
potential for neurodevelopmental and periph-
eral nervous system damage, endocrine dis-
ruption, and cancer (Darnerud et al. 2001;
de Wit 2002; McDonald 2002). Ability of
some PBDEs (BDE-47, BDE-99, BDE-153,
and BDE-209) to disrupt thyroid hormone
homeostasis and adversely affect behavioral
development and cause learning deficits in
rodents is of particular concern regarding
potential exposure (Branchi et al. 2002;
Eriksson et al. 2001, 2002; Lichtensteiger et
al. 2003; Stoker et al. 2003; Viberg et al.
2002). Elevated levels of these compounds
may thus represent a risk, especially to the
developing fetus and nursing newborn. A
recent study in Indiana showed that the indi-
vidual fetal blood concentration did not sub-
stantially differ from the corresponding
maternal concentration, ranging from 15 to
580 ng/g lipid in mothers and from 14 to
460 ng/g lipid in fetal serum (Mazdai et al.
2003). These U.S. levels were 106-fold and
69-fold higher for fetal and maternal serum,
respectively, than levels found in maternal
and fetal blood in a similar Swedish study
(Meironyté Guvenius et al. 2003).
The detection of 200 ng/g lipid of PBDE
congeners in a recent pooled milk sample
(n = 20) from Austin, Texas, and Denver,
Colorado (Päpke et al. 2001), led us to inves-
tigate in more detail the concentration and
distribution of up to 13 PBDE congeners in
milk from 47 individual human milk donors
in Texas.
Materials and Methods
Sample collection. Human milk was obtained
from volunteer U.S. donors between August
and December 2002 from the Austin
Mothers’ Milk Bank in Austin and from
University of Texas Southwestern Medical
Center community women’s health clinics in
Dallas, Texas. We will further refer to sam-
ples from Austin as “milk bank” samples, and
to those from Dallas as “clinic” samples. A
total of 24 milk bank samples from Austin
and 23 clinic samples from Dallas were avail-
able for this study. Milk samples were col-
lected by manual expression in most of the
cases; only a few women used a breast pump.
Information on age, height, weight, and
weeks of nursing was available from most of
the participants, who provided these data and
milk samples after signing the Institutional
Review Board–approved informed consent
documents required by the participating
institutions. Average age was 30.5 years for
the milk bank cohort and was 26.6 years for
the clinic cohort (Table 1). Although informa-
tion on ethnic background and recent as well
as past residence was available for the clinic
cohort in the study, this information was not
available for the milk bank cohort. Of 24 par-
ticipants in the clinic sample, 13 were born in
Mexico. Usually, about 30 mL milk was col-
lected in chemically cleaned glass containers. It
was frozen shortly after collection and shipped
on dry ice to the German and Canadian labo-
ratories for PBDE analysis. The PBDE con-
gener analyses were conducted by two
experienced analytical laboratories, ERGO
Research in Hamburg, Germany, and Health
Canada in Ottawa, Ontario. Both are certiﬁed
by the World Health Organization (WHO)
for congener-specific analysis of dioxins,
dibenzofurans, and PCBs in human milk,
blood, and food (International Comparisons
on Dioxins 2001; WHO 1991).
ERGO Research chemical analyses. The
German laboratory analyzed 13 PBDE con-
geners (BDE-17, BDE-28, BDE-47, BDE-66,
BDE-77, BDE-85, BDE-99, BDE-100,
BDE-138, BDE-153, BDE-154, BDE-183,
and BDE-209) in 23 clinic milk samples from
Dallas. All analyses were performed following
the isotope dilution method. Twelve native
standards (12C-labeled BDE-17, BDE-28,
BDE-47, BDE-66, BDE-77, BDE-85,
BDE-99, BDE-100, BDE-138, BDE-153,
BDE-154, and BDE-183) were obtained from
Cambridge Isotope Laboratories (Andover,
MA, USA). BDE-209 was obtained from
Wellington Laboratories (Guelph, Canada).
Out of seven internal 13C-labeled standards,
six were puchased from Wellington (BDE-28,
BDE-47, BDE-99, BDE-153, BDE-154, and
BDE-183); BDE-209 was obtained from
Cambridge Isotope Laboratories. Silica gel,
alumina oxide, sodium sulfate, and potassium
oxalate of the highest purity commercially
available were used. 
Before extraction, the mixture of seven
internal BDE standards was added to the
sample (500 pg for each congener except
BDE-209, which was 50,000 pg/sample). We
Article | Schecter et al.
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pentane, after adding 5 mL water, 1 mL
potassium oxalate solution, 10 mL ethanol,
and 5 mL ether. The extract was washed with
water and dried over sodium sulfate. After
solvent evaporation, gravimetric lipid deter-
mination was performed. The extract was
cleaned up by acid treatment and passed
through activated silica gel and an alumina
oxide column. The ﬁnal extract was reduced
in volume by a stream of nitrogen. The ﬁnal
volume was 50 µL containing 13C-labeled
BDE-139 for recovery standard. Methods
have been described elsewhere (Päpke et al.
2001; Schroeter-Kermani et al. 2000).
The measurements were performed using
high-resolution gas chromatography/high-res-
olution mass spectrometry at a resolution of
10,000 using a DB-5 column (30 m, 0.25
mm inner diameter, 0.1 µm ﬁlm) for gas chro-
matographic separation. The two most abun-
dant masses were used for measurement (M+
for tri- and tetra-BDE, and M–2Br+ for penta-
to deca-BDE). The identification of PBDEs
was based on retention time and correct iso-
tope ratio. The quantiﬁcation was performed
using internal and external standards.
Reduction of solvents and control of blank
data are important steps in quality control
when analyzing PBDEs in ultratrace levels.
Solvents and reagents were tested before the
laboratory procedures. All glassware was rinsed
with analytical-grade solvents before use. Silica
gel and sodium sulfate were prewashed.
Rotary evaporators were not used in order to
reduce the risk of contamination. No plastic
Article | PBDEs in human milk
Environmental Health Perspectives • VOLUME 111 | NUMBER 14 | November 2003 1725
Table 1. Concentrations of PBDE congeners in breast milk from nursing mothers in Texas in 2001 (ng/g lipid).
Sample Percent Mother’s Nursing PBDE congener
no. lipid age (years) (weeks) 17 28 47 66 77 85 99 100 138 153 154 183 209 ΣPBDE
1a 4.8 31 3 ND 0.2 2.9 0.02 ND 0.08 0.7 0.7 ND 1.5 0.06 ND ND 6.2
2a 1.3 29 3 ND 0.3 3.5 ND ND 0.08 0.7 0.5 ND 0.9 0.06 0.06 ND 6.2
3a 2.1 23 74 ND 0.2 3.9 0.06 ND 0.11 1.5 0.6 ND 0.4 0.08 ND ND 6.9
4b 4.8 32 21 — 0.3 3.5 0.14 — 0.08 1.6 0.7 0.09 1.4 0.09 0.04 — 8.0
5a 2.6 22 40 0.01 0.3 6.3 0.05 ND 0.23 2.8 1.2 ND 0.7 0.20 0.05 ND 11.8
6a 3.6 36 109 ND 0.4 7.8 0.09 ND 0.23 2.4 1.1 0.01 0.4 0.11 ND ND 12.5
7a 1.9 32 20 ND 0.7 8.2 0.04 ND 0.22 1.3 1.7 ND 0.9 0.12 0.08 ND 13.3
8a 6.3 25 2 ND 0.4 7.9 0.02 ND 0.38 2.3 2.7 ND 0.8 0.15 0.06 ND 14.7
9b 2.1 35 29 — 0.7 8.8 0.19 — 0.17 1.5 1.7 0.16 2.0 0.06 0.03 — 15.2
10a 5.5 32 30 ND 0.4 8.0 0.01 ND 0.44 2.9 2.0 ND 0.9 0.14 0.24 0.48 15.6
11a 5.0 20 2 0.01 1.1 10.9 0.05 ND 0.18 2.0 2.4 ND 1.3 0.17 0.04 ND 18.1
12a 3.4 23 3 0.01 0.4 8.0 0.03 ND 0.35 3.1 2.7 ND 2.0 0.21 0.61 0.93 18.3
13b 1.3 32 16 — 0.8 10.5 ND — 0.35 2.5 2.2 0.19 2.0 0.12 0.03 — 18.6
14a 3.4 25 NA 0.02 1.1 12.0 0.13 ND 0.23 2.5 1.8 ND 1.3 0.15 0.08 1.85 21.1
15a 2.9 21 29 0.03 0.5 10.7 0.09 ND 0.27 5.5 2.1 ND 0.9 0.35 0.07 2.74 22.4
16b 3.5 30 30 — 0.7 6.9 ND — 0.12 1.3 4.6 0.41 8.5 0.19 0.06 — 22.8
17a 1.0 23 2 ND 0.9 14.2 0.11 ND 0.37 3.7 2.6 ND 1.3 0.24 0.09 ND 23.5
18b 3.7 23 19 — 0.7 13.2 0.57 — 0.29 3.7 2.5 0.29 1.9 0.17 0.06 — 23.5
19a 3.2 26 2 ND 1.3 17.4 0.19 ND 0.35 4.0 2.1 ND 0.7 0.18 ND ND 26.2
20b 3.5 34 22 — 1.0 14.3 0.29 — 0.46 5.7 3.6 0.25 1.4 0.20 0.10 — 27.3
21b 3.1 33 60 — 1.4 18.4 ND — 0.25 4.1 1.8 0.09 2.1 0.16 0.06 — 28.3
22b 4.9 38 26 — 1.2 17.4 ND — 0.34 7.1 2.3 0.14 0.6 0.30 0.12 — 29.6
23a 3.4 30 2 0.01 0.7 15.2 0.06 ND 0.42 4.2 2.3 ND 3.0 0.22 0.03 3.97 30.1
24a 5.1 28 53 0.01 1.1 20.0 0.18 ND 0.53 5.1 3.9 0.01 2.7 0.32 0.11 ND 34.0
25b 4.7 35 NA — 1.3 20.9 0.56 — 0.31 6.3 2.9 0.14 1.2 0.22 0.17 — 34.1
26a 1.1 41 38 0.02 1.5 19.5 0.11 ND 0.41 3.4 3.3 ND 7.7 0.18 ND ND 36.1
27b 6.1 37 25 — 7.6 17.2 1.19 — 0.35 6.1 2.3 0.18 1.7 0.27 0.05 — 36.8
28b 3.0 27 51 — 1.4 28.2 ND — 0.51 7.5 2.9 0.25 0.7 0.20 0.75 — 42.4
29b 4.8 25 NA — 1.8 21.6 0.94 — 0.50 9.4 4.4 0.47 5.8 0.60 0.06 — 45.5
30b 2.2 39 11 — 1.1 26.8 ND — 0.75 8.9 5.3 0.58 2.0 0.45 0.10 — 46.0
31b 5.6 34 NA — 2.7 31.8 ND — 0.42 7.8 3.1 0.09 0.8 0.22 0.10 — 47.0
32b 3.4 27 10 — 2.6 30.1 0.75 — 0.57 5.9 6.5 0.32 2.5 0.34 0.09 — 49.6
33a 2.8 20 13 0.02 1.1 31.3 0.17 ND 0.13 10.2 5.9 0.02 1.5 0.48 0.11 2.96 53.9
34b 4.0 20 13 — 3.4 33.5 2.32 — 0.49 5.8 5.8 0.27 2.6 0.32 0.06 — 54.6
35b 3.3 26 17 — 1.4 32.3 0.70 — 0.66 9.6 5.7 0.46 12.4 0.51 0.05 — 63.8
36b 2.2 20 16 — 1.4 25.5 0.75 — 0.76 8.0 18.3 1.75 18.3 0.94 0.08 — 75.8
37a 1.1 22 51 0.04 2.2 44.3 0.55 0.03 0.64 10.8 8.1 0.02 14.7 0.56 ND ND 81.9
38b 4.3 29 38 — 5.2 34.8 0.61 — 1.94 9.8 29.2 1.20 14.5 0.96 0.10 — 98.2
39a 1.0 26 22 0.02 1.7 54.7 0.54 ND 1.63 23.6 10.0 ND 4.8 1.15 0.07 ND 98.2
40b 4.9 32 38 — 3.4 49.7 1.21 — 1.20 7.7 21.1 1.40 16.3 0.93 0.15 — 103.1
41b 3.4 30 9 — 3.9 63.1 3.13 — 2.81 30.1 16.2 3.29 17.2 1.94 0.08 — 141.6
42a 1.2 21 2 0.10 10.1 120.9 1.68 0.06 2.64 30.3 20.1 0.13 16.4 2.07 ND ND 204.3
43b 1.2 33 15 — 8.0 139.6 ND — 4.12 44.6 23.0 4.47 21.8 2.76 0.18 — 248.5
44a 1.0 23 2 0.06 3.6 172.4 1.14 ND 6.28 69.8 31.9 0.08 8.4 3.07 0.16 ND 296.9
45b 2.1 34 13 — 7.5 199.6 6.67 — 7.73 108.5 31.7 4.12 6.9 3.62 0.36 — 376.7
46a 1.7 33 47 0.18 6.1 196.2 2.07 0.16 6.46 111.0 31.0 0.27 15.5 7.21 1.32 8.24 385.5
47b 5.1 29 28 — 16.1 271.5 3.16 — 6.29 50.4 47.4 6.86 14.1 2.87 0.12 — 418.8
Mean 28.64 24.56 0.02 2.4 40.8 0.65 0.01 1.15 14.0 8.2 0.60 5.3 0.76 0.13 0.92 73.9
Median 29 20 0.01 1.2 18.4 0.14 NA 0.41 5.7 2.9 0.09 2.0 0.22 0.07 NA 34.0
SD 5.70 22.26 0.04 3.1 59.4 1.19 0.04 1.89 24.6 10.8 1.37 6.1 1.30 0.23 1.96 103.3
Minimum 20 2 ND 0.2 2.9 ND ND 0.08 0.7 0.5 ND 0.4 0.06 ND ND 6.2
Maximum 41 109 0.18 16.1 271.5 6.67 0.16 7.73 111.0 47.4 6.86 21.8 7.21 1.32 8.24 418.8
Abbreviations: NA, not available; ND, not detected. ΣPBDE includes 10 BDE congeners for the Austin samples (BDE-28, BDE-47, BDE-66, BDE-85, BDE-99, BDE-100, BDE-138, BDE-153,
BDE-154, and BDE-183) and three additional congeners for the Dallas samples (BDE-17, BDE-66, and BDE-209).
aDallas samples. bAustin samples.equipment was used. For quality control, a
laboratory blank and a quality control pool of
human milk was run with each batch of 10
samples. Quantiﬁcation was only done if the
sample level was at least twice the blank level.
Health Canada chemical analyses. The
Canadian laboratory analyzed 10 PBDE con-
geners (BDE-28, BDE-47, BDE-66, BDE-85,
BDE-99, BDE-100, BDE-138, BDE-153,
BDE-154, and BDE-183) in 24 milk bank
samples from Austin. Three PBDE congeners,
BDE-17, BDE-77, and BDE-209, were not
measured in this laboratory because levels
below the limit of detection were expected for
these congeners for the majority of milk sam-
ples. Six 13C-labeled BDEs were purchased as
two mixtures from Wellington Laboratories.
Most of the 18 12C-labeled BDE congeners
were obtained from Cambridge Isotope
Laboratories.
A mixture of 500 pg each of six 13C-labeled
PBDE congeners was added to 30 g human
milk (~0.4–1.0 g milk fat). The samples were
homogenized and extracted with acetone–
hexane (a small aliquot was used for the lipid
determination gravimetrically), defatted with
concentrated sulfuric acid, adsorbed on acid
silica, and separated on activated magnesium
silicate. Chromatography on Florisil was
adjusted so that the less polar PCBs were sepa-
rated from the bulk of the PBDEs (Ryan and
Patry 2001; Ryan et al. 2002).
A 30 M methyl silicone gas chromato-
graphic column effected separation of the
mono- to hepta-BDE homologs. Detection
was performed with mass spectrometry in the
electron impact mode at 10,000 resolution
with monitoring of six groups of 5–10 ions
per group of either M+ or M–2Br+ (two ions
per analyte). Quantification was carried out
with isotope dilution using a ﬁve-point linear
calibration curve containing 18 BDE con-
geners, six 13C-labeled BDE surrogates, and
three recovery or performance standards
(PCB-200, PCB-209, and decabromo-
biphenyl). The latter are used to check perfor-
mance of the gas chromatograph and to
calculate recovery of surrogates.
Each batch of 8–10 unknown samples con-
tained a laboratory reagent blank and a quality
control human milk repeat sample. The former
was used to measure the contribution of BDEs
in the laboratory to the total signal, which
was then subtracted from the signal in the
unknown samples before quantiﬁcation. The
repeat human milk quality control sample
was used as an ongoing measure of laboratory
precision and reliability.
Results
Table 1 lists 13 major PBDE congeners, the
sum of all the PBDE congeners (ΣPBDE), per-
centage of lipid in each of the 47 individual
milk samples, age of each mother, and length of
nursing. Table 1 further shows that the range
for the ΣPBDE varied from 6.2 to 419 ng/g
lipid, with a mean of 73.9 ng/g and a median
34.0 ng/g. The table is arranged by increasing
levels of PBDE congeners. We should note the
presence of BDE-209 in 6 of 23 clinic samples,
indicating that despite a lower bioavailability
compared with the other lower brominated
congeners, some of it is absorbed and is present
in human milk samples. BDE-17, BDE-77,
and BDE-209 measured in the clinic samples in
addition to 10 congeners measured in both
milk bank and clinic samples contributed < 1%
to the ΣPBDE; therefore, we present only one
ΣPBDE including all 13 congeners, where
available.
The milk bank participants were on aver-
age about 4 years older than clinic participants
(mean age, 30.5 vs. 26.6 years). ΣPBDE levels
were not correlated with age in the whole 
sample (r = –0.04) or in the milk bank or clinic
samples. The median and mean ΣPBDE levels
in the milk bank samples were 45.8 ng/g and
85.7 ng/g, respectively. In the clinic samples,
the median was 20.4 ng/g and the mean was
61.6 ng/g. BDE-47 contributed most to the
ΣPBDE (54%), followed by BDE-99 (16.8%),
BDE-100 (8.5%), and BDE-153 (5.9%).
We do not know the ethnicity of partici-
pants in the milk bank samples, but informa-
tion obtained from the staff at the milk bank
suggests that the majority of women were
white. In the clinic samples, 13 women were
born in Mexico and have been living in the
United States on average 5.3 years, with a
range from 6 months to 12 years. We did not
observe any substantial difference between
PBDE levels in women born outside the
United States and the rest of the clinic samples.
Hispanic women had similar PBDE levels,
with a median ΣPBDE of 20.4 ng/g compared
with 22.7 ng/g in non-Hispanic women.
The length of time nursing in weeks also
did not seem to correlate with the Σ ΣPBDE
concentrations (r = –0.07) in the whole sam-
ple or in the milk bank or clinic samples. The
length of the most recent nursing was shorter
in the clinic group (26.6 vs. 30.6 weeks), but
six of the clinic sample participants had been
nursing only for about 2 weeks when milk
was collected. The correlation did not change
substantially when the total length of lacta-
tion for all children was used in calculations.
The number of children of subjects did not
correlate with the PBDE concentrations (data
not shown).
In Figure 1, the ΣPBDE concentrations are
shown in quartiles, from minimum to maxi-
mum. Figure 2 shows the ΣPBDE concentra-
tions for each of the 47 women. Fifteen of the
samples (32%) contain ΣPBDE > 50 ng/g, and
the highest 10 samples contain ≥ 100 ng/g; the
highest level of ΣPBDE in milk in these sam-
ples is 419 ng/g. Figure 3 shows a comparison
of levels of BDE-47, BDE-99, and BDE-153
in human milk between several countries.
Values for Germany (Schroeter-Kermani et al
2000), Canada (Ryan et al 2002; Ryan and
Patry 2001), Sweden (Noren and Merionyte
2000), and Finland (Strandman et al. 2000)
are compared with the U.S. data, showing
higher levels for each in the U.S. milk.
Discussion
This is the ﬁrst study of PBDEs in individual
U.S. mothers’ milk. Up to 13 PBDE congeners
were analyzed in human milk from 47 individ-
ual women in the general population from two
sources in Texas, a milk bank in Austin and
community women’s health clinics in Dallas.
The findings show extremely elevated levels
(10–100 times) in many participants compared
with contemporaneous levels reported in
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Figure 1. PBDE concentrations in U.S. human milk
samples from 2002 by percentile (n = 47; ng/g lipid). Figure 2. PBDE concentrations in individual U.S. human milk samples from 2002 (ng/g lipid).Europe (Darnerud et al. 2001; Meironyté
Guvenius et al. 1999; Schroeter-Kermani et al.
2000; Strandman et al. 2000; Thomsen et al.
2002). They also show very elevated levels in
many of the women with no known occupa-
tional exposure. The women were white,
African American, and Hispanic in origin. We
found no apparent difference in concentrations
between age groups or ethnic groups, but even
though this is the largest individual U.S.
human milk study for PBDEs, it is still a rela-
tively small sample. The milk bank and clinic
samples were analyzed by two experienced lab-
oratories that had participated in numerous
interlaboratory dioxin and dibenzofuran qual-
ity control studies (International Comparisons
on Dioxins 2001; WHO 1991), but some of
the differences observed could be due to differ-
ent methodologies used. A human milk inter-
laboratory study conducted by the Canadian
and German laboratories after our study was
completed reported almost identical congener
levels when using a pooled milk sample (Päpke
O, Ryan JJ. Personal communication). 
Two recent U.S. studies in California
(Petreas et al. 2003) and Indiana (Mazdai et al.
2003) have measured PBDE levels in blood
samples and adipose tissue and in fetal and
maternal serum samples. Levels found in these
two studies were also reported on a lipid basis
and are similar in range to those found in the
present study. These results suggest that there
appears to be a similar range in different parts
of the United States and that U.S. PBDE levels
are at least 10 times and up to 100 times
higher than those found in Europe. Data on
potential sources of exposure indicate that
PBDEs are present in food (Asplund et al.
1999; Huwe et al. 2000; Jacobs et al. 2001;
Johnson and Olson 2001; Lind et al. 2002;
Ohta et al. 2002; Zegers et al. 2001), land
sludge (Pardini et al. 2001), and dust (Knoth
et al. 2002; Leonards et al. 2001). It remains to
be shown whether or not food represents a
major source of PBDEs as it does with dioxins
(Schecter 1994; Schecter and Gasiewicz 2003;
Startin 1994; U.S. EPA 1984). In a recently
published paper, Sjödin et al. (2003) reviewed
human exposure to brominated flame retar-
dants, especially PBDEs.
At present, only one study (n = 15) exam-
ined the partitioning ratio of PBDE con-
geners between adipose tissue, milk, and
blood (Meironyté Guvenius et al. 2003). The
results suggest that partitioning is close to 1:1.
The partitioning previously reported for
dioxin and dibenzofuran congeners varied in
blood and adipose tissue from approximately
1:1 for 2,3,7,8-tetrachlorodibenzo-p-dioxin
(2,3,7,8-TCDD), to 2:1 for octachlorinated
dibenzodioxin (Schecter et al. 1991, 1998).
The partitioning of persistent lipophilic com-
pounds, including dioxins, between human
milk and blood lipid was recently reviewed by
Aylward et al. (2003). Schecter et al. (1989)
have also shown that the partitioning of diox-
ins and related compounds in various organs
of the human body is not always 1:1. Further
studies should be conducted to more precisely
estimate the partitioning for PBDE congeners
and to increase conﬁdence in using different
matrices to estimate body burden.
The purpose of this study was to determine
whether U.S. women have higher, equal, or
lower milk PBDE levels than women in other
countries. The answer is striking: the 47 indi-
vidual U.S. women studied here had markedly
higher levels in their breast milk compared to
Europeans. This survey clearly indicates that
high levels of PBDEs are found in U.S. women
and can be transferred to the nursing infants,
as shown recently by Mazdai et al. (2003) and
Meironyté Guvenius et al. (2003). The effects
of age, previous nursing, and food on levels of
PBDEs in humans needs to be determined.
This study, like the California study (Petreas et
al. 2003) and the Swedish (Darnerud et al.
1998) and Norwegian (Thomsen et al. 2002)
studies, did not show a positive association
with age as has been found with dioxins, PCBs,
and other POPs. Even though this association
was not tested on a sufﬁciently large sample to
draw a definitive conclusion, data from this
and other studies appear to support a lack of
increase in PBDE levels with age. Similar to
age, and again unlike dioxins and PCBs, length
of lactation did not seem to be associated with
the PBDE levels. Whether this is because of
the relatively short history of intensive PBDE
use remains to be determined.
It should be noted that the current use of
brominated ﬂame retardants is the result of a
need for safer consumer products, that is,
products that are less likely to burn in ﬁres. It
is estimated that many deaths are avoided in
the United States each year by the use of
brominated ﬂame retardants, and children are
at special risk of death and injury in ﬁres.
Further studies need to be conducted on
PBDE levels in milk and blood, in women
from different locations, of ethnic groups and
different ages, and with different nursing histo-
ries, as well as in males and children. Health
consequences to the nursing infant as well as
the adult from PBDEs at the levels found need
further study. There are particular concerns
especially about infant health because the fetus
and the developing child are more sensitive
than adults to the effects of exogenous chemi-
cal compounds, including PBDEs in breast
milk or diet. Measurement of PBDE levels in
meat, ﬁsh, dairy products, air, and dust should
help determine routes of exposure, adding to
the limited data available today (Asplund et al.
1999; Huwe et al. 2000; Jacobs et al. 2001;
Johnson and Olson 2001; Knoth et al. 2002;
Leonards et al. 2001; Lind et al. 2002; Ohta et
al. 2002; Zegers et al. 2001). Occupational
health studies of potentially exposed workers
may also be helpful in identifying the source of
these persistent and toxic halogenated organics.
Clearly, much further research is needed to
determine the levels and distribution of PBDEs
in the U.S. population, routes of intake, and
their health effects.
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